



Current status of urine samples to monitor HPV vaccination status.

Laura Téblick, Alex Vorsters

Why first-void urine (FVU)?




First-void urine




HPV DNA




Methylation markers



HPV-specific antibodies




HPV virions




Initial stream of urine

Captures impurities lining the urethra opening including transudated **antibodies** and **biomarker**-containing mucus and debris from exfoliated cells originating from **female** genital organs

- ✓ Non-invasive
- ✓ Likely preferred
- ✓ Home-based
- ✓ Reaches screening/follow-up non-participants



First-void urine



Article

Long-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing

Alex Vorsters^{1,*}, Severien Van Keer¹, Samantha Biesmans¹, Annick Hens¹, Ilse De Coster¹, Herman Goossens^{2,3}, Margareta Ieven^{2,3} and Pierre Van Damme¹



VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples

M. Arbyn^{a,*}, E. Peeters^a, I. Benoy^{b,c,d}, D. Vanden Broeck^{b,c,d,e}, J. Bogers^{b,c,d,e}, P. De Sutter^f, G. Donders^{g,h,i}, W. Tjalma^{h,i}, S. Weyers^j, K. Cuschieri^m, M. Poljak^k, J. Bonde^l, C. Cocuzzaⁿ, F.H. Zhao^o, S. Van Keer^a, A. Vorsters^a

Optimization of HPV DNA detection in urine by improving collection, storage, and extraction

A. Vorsters · J. Van den Bergh · I. Micalessi · S. Biesmans · J. Bogers · A. Hens · I. De Coster · M. Ieven · P. Van Damme

Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda

Silvia Franceschi¹, M. Chantal Umulisa², Ugyen Tshomo³, Tarik Gheit⁴, Iacopo Baussano¹, Vanessa Tenet¹, Tshokey Tshokey⁴, Maurice Gatera², Fidele Ngabo², Pierre Van Damme⁵, Peter J.F. Snijders⁶, Massimo Tommasino¹, Alex Vorsters⁵ and Gary M. Clifford¹

Urine testing for HPV: rationale for using first void

Alex Vorsters *researcher*¹, Pierre Van Damme *professor*¹, Gary Clifford *cancer epidemiologist*²

¹Faculty of Medicine and Health Sciences, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, 2610 Antwerpen (Wilrijk), Belgium; ²Infections and Cancer Epidemiology Group, International Agency for Research on Cancer, Lyon, Cedex 08, France



Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol

Severien Van Keer^{a,*}, Eliana Peeters^b, Davy Vanden Broeck^{c,d,e,f}, Philippe De Sutter^g, Gilbert Donders^{h,i,j}, Jean Doyen^k, Wiebren A.A. Tjalma^{l,m}, Steven Weyersⁿ, Alex Vorsters^a, Marc Arbyn^b

Impact of Collection Volume and DNA Extraction Method on the Detection of Biomarkers and HPV DNA in First-Void Urine

Laura Téblick^{1,*}, Severien Van Keer¹, Annemie De Smet¹, Pierre Van Damme¹, Michelle Laeremans², Alejandra Rios Cortes², Koen Beyers², Vanessa Vankerckhoven^{1,2}, Veerle Matheussen^{3,4,5}, Renee Mandersloot⁶, Arno Floore⁶, Chris J. L. M. Meijer^{6,7}, Renske D. M. Steenbergen^{7,8} and Alex Vorsters^{1,9}

Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan

Iacopo Baussano, Felix Sayinzoga, Ugyen Tshomo, Vanessa Tenet, Alex Vorsters, Daniëlle A.M. Heideman, Tarik Gheit, Massimo Tommasino, Marie Chantal Umulisa, Silvia Franceschi, Gary M. Clifford



Human papillomavirus detection in urine: Effect of a first-void urine collection device and timing of collection

Jade Pattyn^{a,*}, Severien Van Keer^a, Samantha Biesmans^a, Margareta Ieven^{b,c}, Charlotte Vanderborght^a, Koen Beyers^a, Vanessa Vankerckhoven^{a,b}, Robin Bruyndonckx^{c,d}, Pierre Van Damme^a, Alex Vorsters^a

HPV DNA detection in urine samples of women: 'an efficacious and accurate alternative to cervical samples?'

Jade Pattyn, Severien Van Keer, Laura Téblick, Pierre Van Damme & Alex Vorsters

European Journal of Clinical Microbiology & Infectious Diseases (2018) 37:859–869
https://doi.org/10.1007/s10996-017-3179-1

ORIGINAL ARTICLE



Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples


Severien Van Keer^{1,*}, Wiebren A. A. Tjalma^{2,3}, Jade Pattyn¹, Samantha Biesmans¹, Zoë Pieters^{4,5}, Xaveer Van Oostede⁶, Margareta Ieven⁷, Pierre Van Damme¹, Alex Vorsters¹




First-void urine




Methylation markers



HPV-specific antibodies



HPV virions



First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions

Severien Van Keer^{a,*}, Martina Willhauck-Fleckenstein^b, Jade Pattyn^a, Julia Butt^b, Wiebren A.A. Tjalma^{a,d}, Xaveer Van Ostade^c, Niel Hens^{a,e}, Pierre Van Damme^a, Tim Waterboer^b, Alex Vorsters^a

Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine

Jade Pattyn¹ | Gitika Panicker² | Martina Willhauck-Fleckenstein³ | Severien Van Keer¹ | Laura Téblick¹ | Zoë Pieters^{4,5} | Wiebren A. A. Tjalma^{6,7} | Veerle Matheeußen^{8,9,10} | Pierre Van Damme¹ | Tim Waterboer³ | Elizabeth R. Unger² | Alex Vorsters¹

Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature

Jade Pattyn^{a,*}, Severien Van Keer^a, Wiebren Tjalma^a, Veerle Matheeußen^a, Pierre Van Damme^a, Alex Vorsters^a

Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine

Jade Pattyn^a, Severien Van Keer^a, Laura Téblick^a, Pierre Van Damme^a and Alex Vorsters^a

Faculty of Medicine and Health Sciences, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium

HPV-specific antibodies are detectable in FVU samples

HPV-specific antibody concentrations detected in FVU correlate with concentrations in serum

Major presence of IgG in female genital tract


- 90% reduction of total IgG in genital tract secretions after total hysterectomy

Ab transport mechanism blood → FVU

- Exudation
- Transudation
- Receptor mediated: FcRn receptor

AB-SOP follow-up study / 2018-2022

NCT03542227



Samples
1 (3) serum + 3 FVU

Mean age at inclusion
35y (IQR: 28 - 41)

Vaccine type:
100% 9vHPV

AB-SOP follow-up study / 2018-2022


NCT03542227

HPV-specific antibody detection

- M9ELISA at CDC
- Multiplex VLP based IgG assay for HPV types included in the nonavalent HPV-vaccine
- Multiarray plates: spotted at Meso Scale Discovery
- Concentrations calculated using
→ Parallel line (PLL) method
- International and arbitrary units (IU/ml and AU/ml)

HPV DNA Detection

1. **All FVU samples:** Roche Cobas 6800 (HPV16/18/otherHrHPV)
2. **Cobas 6800 positive samples:** Riatol qPCR HPV genotyping assay (HPV6/11/16/18/31/33/35/39/45/51/52/53/56/58/59/66/68/67)



AB-SOP follow-up study / 2018-2022

NCT03542227


M9ELISA

HPV type	FIRST-VOID URINE		
	Month 0	Month 7	Month 44
	Uropositivity (positive/total (%))	Uropositivity (positive/total (%))	Uropositivity (positive/total (%))
6	11/63 (17%)	62/63 (98%)	57/58 (98%)
11	6/63 (10%)	63/63 (100%)	57/58 (98%)
16	8/63 (13%)	63/63 (100%)	58/58 (100%)
18	8/63 (13%)	61/63 (97%)	52/58 (90%)
31	6/63 (10%)	63/63 (100%)	55/58 (95%)
33	4/63 (6%)	63/63 (100%)	56/58 (97%)
45	2/63 (3%)	60/63 (95%)	52/58 (90%)
52	0/63 (0%)	62/63 (98%)	49/58 (84%)
58	5/63 (8%)	63/63 (100%)	53/58 (91%)

AB-SOP follow-up study / 2018-2022

NCT03542227


M9ELISA



AB-SOP follow-up study / 2018-2022

NCT03542227

M9ELISA




UNPUBLISHED DATA – DO NOT COPY OR DISTRIBUTE

AB-SOP follow-up study / 2018-2022

NCT03542227

M9ELISA



AB-SOP follow-up study / 2018-2022

NCT03542227

1. All samples: Roche Cobas 6800

2. Riatol qPCR HPV genotyping assay


4/63 women had an
infection of HPV
type included in
nonavalent vaccine

= red

ID	Before vaccination	7M after 1st dose	44M after 1st dose
14	HPV59	HPV59	HPV other
19	None	None	/
24	/	HPV66	/
28	/	HPV52	/
31	HPV33, HPV59	/	/
35	HPV51	HPV51	/
37	HPV56	HPV56	/
45	/	/	HPV other
48	/	/	HPV other
51	HPV16, HPV33, HPV51	HPV16, HPV33, HPV51, HPV56, HPV66	HPV16, HPV other
60	HPV31, HPV51	HPV35, HPV51	/
62	HPV51	/	/

AB-SOP follow-up study / 2018-2022

NCT03542227




4/63 women had an
infection of HPV type
included in nonavalent
vaccine

= red



First-void urine




Concluding remarks

1. Follow-up of vaccination using FVU samples
 - Promising data
 - Normalisation is being investigated
2. Good correlation between HPV-specific antibody concentrations in FVU and serum
3. First-void urine has potential to become the **“golden sample”** for both detecting HPV infection and monitoring HPV vaccination
(Also anti-HIV antibodies can be detected in urine)



University of Antwerp

Centre for the Evaluation of Vaccination
Vaccine and Infectious Disease Institute



Centers for Disease
Control and Prevention

Special thanks to

HPV team at the Centre for the Evaluation of Vaccination (CEV):

Severien Van Keer, PhD; Jade Pattyn, PhD; Annemie De Smet;
Prof. Alex Vorsters, PhD

Centers for Disease Control and Prevention (CDC):

Gitika Panicker, PhD; Prof. Elizabeth Ünger, MD, PhD

Funding

- Industrial Research Fund of the University of Antwerp, Belgium
- The Research Foundation.- Flanders (FWO), Belgium (Junior postdoctoral fellowship S. Van Keer)



Current status of urine samples to monitor HPV vaccination status.

Laura Téblick, Alex Vorsters